- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06149468
CAP48 - Autism in Children and Adolescents (CAP48-ASD)
May 22, 2025 updated by: Université Catholique de Louvain
CAP48 Medical Research Project: Autism Spectrum Disorders in Children and Adolescents
Evaluation and follow-up of children diagnosed with an autism spectrum disorder in French-speaking Belgium in order to optimize diagnostic protocols, the quality of care required and its accessibility, and to determine the impact of an autism spectrum disorder on schooling, family and society.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The aims of the research project:
- To collect a wide range of data in order to improve knowledge of children with autism spectrum disorder (ASD) in French-speaking Belgium by prospectively including all children and adolescents making a request to the centres of reference. The creation of a common database will make it possible to collect general socio-demographic, geographical and epidemiological data, to characterise the different profiles and to accurately monitor developmental trajectories.
- Evaluate the feasibility and practical implementation of the treatment proposed following a diagnosis of ASD in a child.
- Implement protocols to improve the quality of care for beneficiaries.
- To enable the development of fundamental research protocols. Many questions remain unanswered about the genetic, neuro-cognitive and linguistic characteristics of autism. Only rigorous studies carried out on large, carefully defined samples can advance research.
- Increase public knowledge and understanding of the ASD.
Study Type
Observational
Enrollment (Estimated)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Marie-Cécile Nassogne, Prof
- Phone Number: 027641061
- Email: marie-cecile.nassogne@saintluc.uclouvain.be
Study Contact Backup
- Name: Marine Houssa, PhD
- Phone Number: 74688 010474688
- Email: marine.houssa@uclouvain.be
Study Locations
-
-
-
Bruxelles, Belgium
- Recruiting
- UCLouvain
-
Contact:
- Marine Houssa, PhD
- Phone Number: 74688 010474688
- Email: marine.houssa@uclouvain.be
-
Contact:
- Marie-Cécile Nassogne, Prof
- Phone Number: 02 764 1061
- Email: marie-cecile.nassogne@saintluc.uclouvain.be
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
children/adolescents (under 18 years of age) who apply to an autism reference center or who are followed up in an autism reference center.
Description
Inclusion Criteria:
- children/adolescents (under 18 years of age) who apply to an autism reference center or who are followed up in an autism reference center from French-speaking region of Belgium.
Exclusion Criteria:
- refusal by the family to allow their child's data to be included in the database.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
ASD group
child/adolescent (under 18 years of age) applying to an autism reference center or being followed up in an autism reference center
|
socio-demographic data collection and proposed therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Creation of an ADS register
Time Frame: Throughout the entire study, approximately during 5 years
|
creation of a common ASD register to collect general sociodemographic, geographic and epidemiological data, characterize the different patient profiles and accurately track development trajectories
|
Throughout the entire study, approximately during 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasability assessment
Time Frame: Throughout the entire study, approximately during 5 years
|
Evaluate the feasibility and practical realization of the proposed care following a diagnosis of ASD in a child and implement protocols to improve the quality of therapy.
|
Throughout the entire study, approximately during 5 years
|
|
Protocols development
Time Frame: Throughout the entire study, approximately during 5 years
|
Enable the development of fundamental research protocols: genetic, neurocognitive and linguistic
|
Throughout the entire study, approximately during 5 years
|
|
Schooling evaluation
Time Frame: Throughout the entire study, approximately during 5 years
|
Evaluate the schooling of children with ASD of all ages
|
Throughout the entire study, approximately during 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Marine Houssa, PhD, Université Catholique de Louvain
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 15, 2023
Primary Completion (Estimated)
December 31, 2028
Study Completion (Estimated)
December 31, 2028
Study Registration Dates
First Submitted
November 20, 2023
First Submitted That Met QC Criteria
November 20, 2023
First Posted (Actual)
November 29, 2023
Study Record Updates
Last Update Posted (Actual)
May 29, 2025
Last Update Submitted That Met QC Criteria
May 22, 2025
Last Verified
May 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAP48 - TSA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Istituto Clinico HumanitasRecruitingAutism | Autism Spectrum Disorder (ASD) | Autism DisorderItaly
-
Greater Atlanta Integrative PediatricsRecruitingAutism Spectrum Disorder | Autism | ASD | Autism Spectrum Disorder (ASD)United States
-
The Children's Hospital of Zhejiang University...Not yet recruitingAutism | Autism Spectrum Disorder (ASD)China
-
Poznan University of Physical EducationCompletedAutism | Autism Spectrum Disorder (ASD)Poland
-
Adia Med of Winter Park LLCRecruitingAutism Spectrum Disorder | Autism | ASD | Autism Spectrum Disorder (ASD)United States
-
Poznan University of Physical EducationNational Science Centre, PolandCompletedAutism Spectrum Disorder | ASD | Autism Spectrum Disorder High-Functioning | Autism SpectrumPoland
-
Stanford UniversityJohn and Marcia Goldman FoundationNot yet recruitingAutism | Autism Spectrum Disorder (ASD)United States
-
Blinklab LimitedRecruitingAutism Spectrum Disorder | Autism | Neurodevelopmental Conditions | Autism Spectrum Disorder (ASD)United States
-
National Cheng-Kung University HospitalCompletedAutism Spectrum Disorder (ASD) | Autism Spectrum Disorder High-FunctioningTaiwan
-
University of California, Los AngelesUniversity of WashingtonRecruitingAutism Spectrum Disorder (ASD)United States
Clinical Trials on inclusion in the register
-
Institut Claudius RegaudUnknownHereditary Breast and Ovarian Cancer | Hereditary Cancer Syndrome | Hereditary Colorectal Endometrial Cancer SyndromeFrance
-
Fundación Pública Andaluza para la gestión de la...CompletedMobile Applications | Preoperative Period | Internet-Based InterventionSpain
-
Fondation Ophtalmologique Adolphe de RothschildRecruiting
-
European Vaccine InitiativeKintampo Health Research Centre, Ghana; Groupe de Recherche Action en Sante; Fondation... and other collaboratorsCompletedPregnancy RelatedBurkina Faso, Benin, Ghana, Malawi
-
Jacqueline Gartner-SchmidtCompletedVocal Fold Polyp | Vocal Cord Cyst | Voice and Resonance Disorders | Vocal Cord Polyp | Atrophy of Vocal CordUnited States
-
Washington University School of MedicineUniversity of Iowa; Christiana Care Health Services; University of CincinnatiCompletedRespiratory Failure | Acute Lung Injury | Mechanical VentilationUnited States
-
Xuzhou Central HospitalCompletedAcute Myocardial Infarction (AMI) | Major Adverse Cardiovascular Events | Red Blood Cell Distribution Width-to-albumin RatioChina
-
University of Sao PauloCompletedCongenital Heart DiseaseBrazil
-
Centre Hospitalier Universitaire de la GuadeloupeRecruiting
-
Zimmer BiometCompletedRheumatoid Arthritis | Osteonecrosis | Osteoarthritis, Hip | Post-traumatic; Arthrosis | Fracture of Hip | Dislocated Hip | Subluxation Hip